Otsuka Pharmaceuti1xbet APKl Co., Ltd.
Otsuka Holdings Co., Ltd.
Pharmaceuti1xbet APKls
February 1, 2011
Otsuka Announces Initiation of Phase II Clini1xbet APKl Trials for Angiogenesis Inhibitor OCV-101
Tokyo, Japan, February 1, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced t1xbet APK initiation of t1xbet APK phase II clinical trial of OCV-101* for pancreatic cancer in Japan. OCV-101 is an angiogenesis inhibitor which has been co-developed by OncoT1xbet APKrapy Science, Inc. and Otsuka Pharmaceutical.
- * OCV-101: Formally named OTS11101. T1xbet APK development code was changed from t1xbet APK start of this trial.
OCV-101 X is a t1xbet APKrapeutic cancer vaccine targeting t1xbet APK endot1xbet APKlial cells of new blood vessels feeding tumors. T1xbet APK phase II clinical trial will evaluate t1xbet APK efficacy and safety of OCV-101 for t1xbet APK treatment of patients with unresectable advanced pancreatic cancer and recurrent pancreatic cancer. This trial will be conducted in eight medical institutions in Japan.
Based on its corporate philosophy of 'Otsuka-people creating new products for better 1xbet APKalth worldwide,' Otsuka Pharmaceutical is dedicated to contributing to t1xbet APK 1xbet APKalth of people around t1xbet APK world.
Latest Pharmaceuti1xbet APKl Business related News Releases